Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM)

Victory Capital Management Inc. raised its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 39.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 493,288 shares of the company’s stock after buying an additional 138,526 shares during the period. Victory Capital Management Inc. owned about 0.82% of Immunome worth $5,969,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Redmile Group LLC raised its holdings in Immunome by 26.0% in the 1st quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock worth $120,674,000 after purchasing an additional 1,010,139 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Immunome by 113.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after acquiring an additional 1,194,451 shares during the period. Vanguard Group Inc. increased its holdings in Immunome by 16.1% in the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock worth $49,847,000 after acquiring an additional 279,712 shares in the last quarter. Janus Henderson Group PLC raised its stake in Immunome by 10.6% during the 1st quarter. Janus Henderson Group PLC now owns 1,538,414 shares of the company’s stock worth $37,957,000 after acquiring an additional 146,943 shares during the period. Finally, Avidity Partners Management LP purchased a new position in Immunome during the fourth quarter valued at approximately $14,268,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Performance

IMNM stock opened at $15.97 on Monday. The company has a market capitalization of $957.70 million, a PE ratio of -2.12 and a beta of 1.77. The company’s fifty day moving average price is $14.27 and its 200-day moving average price is $16.38. Immunome, Inc. has a one year low of $6.65 and a one year high of $30.96.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The company had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.62 million. On average, research analysts predict that Immunome, Inc. will post -1.92 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In other news, Director Jean Jacques Bienaime acquired 7,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $13.94 per share, with a total value of $97,580.00. Following the acquisition, the director now directly owns 16,615 shares of the company’s stock, valued at $231,613.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Immunome news, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the transaction, the insider now directly owns 16,000 shares of the company’s stock, valued at approximately $222,880. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the director now owns 16,615 shares in the company, valued at $231,613.10. The disclosure for this purchase can be found here. 8.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Tuesday, August 13th. Piper Sandler cut their price target on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $29.00.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.